Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (<i>nab</i>-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).Douglas R. Adkins, D. I. Kuperman, T. Rachocki et al.|Journal of Clinical Oncology|2011Cited by 6
Clinical response rate at primary tumor site by WHO criteria following an induction chemotherapy regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC).D. I. Kuperman, Douglas R. Adkins, Jessica Ley et al.|Journal of Clinical Oncology|2010Cited by 2
Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC) with APF (<i>nab-</i>paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF+Cetux) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).Jessica Ley, Douglas R. Adkins, Brian Nussenbaum et al.|Journal of Clinical Oncology|2014Cited by 2
The role of cetuximab in induction chemotherapy: Comparison of APF-C (<i>nab-</i>paclitaxel, cisplatin, 5-FU + cetuximab) with APF, both followed by chemoradiation therapy (CRT), in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).Douglas R. Adkins, Brian Nussenbaum, Jessica Ley et al.|Journal of Clinical Oncology|2015Cited by 1
Efficacy of cetuximab-based second-line therapy in patients with metastatic head and neck squamous cell carcinoma (HNSCC) which progressed on gefitinib-based first-line therapyJennifer Mosley, Douglas R. Adkins, D. Seckfort et al.|Journal of Clinical Oncology|2008Cited by 0